Pharmacologist and translational drug-development leader (PhD, PharmD) with 14+ years moving assets from discovery to IND and FIH across oncology, radiopharmaceuticals, immuno-oncology, genetic engineering, and precision medicine. I lead cross-functional pharmacology/biomarker strategy, direct GLP/GCLP studies, and author CTD modules for FDA, EMA, and Health Canada.
Led >25 preclinical programs; integrated PK/PD, biodistribution, histology to drive dose selection and target engagement.
Regulatory-facing scientist: successful FDA Type B, EMA advice, HC CTA inputs; deliver IND/CTA-ready packages.
Team builder & mentor: established governance, SOPs, and training to raise execution quality.
Funding & BD: secured >$1M in internal + non-dilutive R&D; co-crafted proposals and scientific narratives; frequent KOL/board presenter.
Track record: 10+ publications (incl. Cancer Cell, Cell Chem Biol), US patent co-inventor, Chairman Rising Star (’25) & Budding Innovator (’24).
Focus areas: Translational/clinical pharmacology, biomarker strategy, radiopharma, IND enablement, CRO governance, and cross-functional leadership.